GLP-1 Drugs Must Carry a New Eye-Risk Warning. The Price Did Not Fall.

Patients using GLP-1 drugs got a safety update on Monday, not a lower price.

CNBC reported that the Food and Drug Administration said Eli Lilly and Novo Nordisk must add warnings to their current GLP-1 medicines about a higher risk of a serious eye condition. The report described the side effect as rare, based on incidence figures cited by the FDA. It did not name the condition or print the rate. A Lilly spokesperson said patient safety is the company's priority, that the notice covers all medicines with GLP-1 activity, and that it does not cite findings specific to Lilly.

Separately, Lilly said its weight-loss pill Foundayo reduced the severity of obstructive sleep apnea in a late-stage study of adults with obesity. Lilly plans to ask the FDA by year-end to add that use. A wider label can matter later for insurance coverage. It is not a discount. No list price or copay was changed.

Did Monday's warning or the Foundayo study change what a patient pays? No price or insurance-premium cut was announced. The verified steps are a new warning requirement and a planned request for a broader Foundayo label.